Hepatic Encephalopathy: A Step-by-Step Guide to Diagnosis and Treatment on the Wards

You walk into the ED to see your next patient, a 48-year-old man brought in by EMS for altered mental status. The paramedics tell you his neighbor called 911 because he’d been acting strangely for a few days and wasn't sleeping.

On exam, he’s somnolent, responding only to a firm shoulder shake, but he’s not following commands or making sense. You notice significant ascites. His vitals are concerning: BP 96/70 mmHg, HR 111/min, and SpO2 95% on room air.

A quick fingerstick glucose reads 55 mg/dL, and his initial labs show hyponatremia (126 mmol/L) and hypokalemia (2.9 mmol/L). You learn he has a long history of alcohol-associated liver disease.

This clinical picture is a classic for your boards and your wards. Let's break down hepatic encephalopathy (HE), a must-know diagnosis for any student or resident.

What is Hepatic Encephalopathy? A Brain in Crisis

Hepatic encephalopathy isn't a single disease but a spectrum of neuropsychiatric abnormalities seen in patients with severe liver dysfunction. When the liver fails, it can no longer do its crucial job of detoxification.

The key culprit is ammonia. Normally, the liver converts ammonia (a byproduct of protein digestion in the gut) into urea, which is then safely excreted by the kidneys. In advanced liver disease, this process breaks down. Ammonia levels in the blood rise, cross the blood-brain barrier, and wreak havoc on the central nervous system. Inside the brain, ammonia disrupts neurotransmitter balance, leading to the confusion, lethargy, and other neurological signs we see clinically.

Recognizing HE is critical. While it's a sign of severe, life-threatening liver failure, it's often reversible with prompt treatment.

Spotting the Signs: From Subtle Changes to Coma

HE can be sneaky. The symptoms range from barely noticeable to profound coma. We often grade the severity using the West Haven Criteria (Grades 0-4).

• Grade 1 (Mild): Minor changes in personality, shortened attention span, irritability, and a disturbed sleep-wake cycle (e.g., sleeping all day, awake all night).

• Grade 2 (Moderate): Lethargy, disorientation, inappropriate behavior, and the classic physical finding: asterixis. This is the "flapping tremor" you see when a patient extends their wrists.

• Stage 3 Hepatic Encephalopathy: The patient is very somnolent but arousable. They are markedly confused, unable to follow commands, and may have slurred speech. Asterixis is usually present if the patient can cooperate.

• Grade 4 (Coma): The patient is unresponsive, even to painful stimuli.

For your exams, you need to recognize this progression. On the wards, you'll see patients across this entire spectrum.

Why Does This Happen? The Usual Suspects & Triggers

HE can develop in both acute liver failure and, more commonly, as an acute-on-chronic event in patients with cirrhosis. While the underlying cause of liver disease can vary (viral hepatitis, autoimmune disease, drug-induced injury), the most common etiology you'll encounter in the US is alcohol-associated liver disease.

In a patient with known cirrhosis, HE doesn't just happen randomly. It's almost always kicked off by a specific precipitating event. Your job is to be a detective and find that trigger. The most common ones are:

• Infections: Spontaneous bacterial peritonitis (SBP), urinary tract infections, pneumonia.

• GI Bleeding: Blood in the gut is a huge protein load, leading to a surge in ammonia production by gut bacteria.

• Electrolyte Disturbances: Especially hypokalemia and hyponatremia.

• Dehydration & Acute Kidney Injury: Reduces clearance of toxins.

• Constipation: Increased intestinal transit time allows for more ammonia absorption.

• Medications: Overuse of diuretics, or new prescriptions for sedatives like benzodiazepines or opioids.

Finding and treating the trigger is just as important as treating the HE itself.

The Diagnostic Workup: A Diagnosis of Exclusion

There is no single test that screams "hepatic encephalopathy." It is fundamentally a diagnosis of exclusion. This means your primary goal is to rule out other life-threatening causes of altered mental status. The differential diagnosis of confusion is broad, so your workup needs to be thorough.

Initial Labs to Order:

• Complete Blood Count (CBC): To look for signs of infection or anemia from a GI bleed.

• Basic Metabolic Panel (BMP): Crucial for identifying electrolyte abnormalities (Na+, K+), renal failure (BUN, Creatinine), and hypoglycemia.

• Liver Function Tests (LFTs) & Bilirubin: To assess the degree of liver injury. High-yield tip: In end-stage cirrhosis, the AST and ALT may be only mildly elevated or even normal as there are few healthy hepatocytes left.

• Coagulation Panel (PT/INR): The INR is a true measure of the liver's synthetic function. A high INR (not due to anticoagulants) is a hallmark of liver failure.

• Inflammatory Markers (e.g., CRP): Can point toward an underlying infection.

To Check Ammonia or Not? The Million-Dollar Question

This is a common point of confusion. While ammonia is central to the pathophysiology, routine checking of serum ammonia levels is controversial.

• A normal ammonia level has a high negative predictive value. If your patient is in a coma (Grade 4 HE) and their ammonia level is normal, the diagnosis of HE is unlikely. You need to aggressively search for another cause.

• An elevated ammonia level does NOT confirm HE. Many patients with cirrhosis have chronically elevated ammonia without any neurological symptoms. Furthermore, studies have shown that up to 40% of patients with confirmed HE can have normal serum ammonia levels.

• The level does not correlate with severity. A patient with a very high level might be only mildly confused, while a patient with a slightly elevated level could be comatose. You cannot use ammonia levels to monitor response to treatment.

The bottom line: An ammonia level can sometimes be helpful if the diagnosis is uncertain. A low level might push you to look for other causes. However, in a patient with known cirrhosis and a classic clinical picture, it rarely changes your immediate management in the ED.

Don't forget to consider:

• Rectal Exam: To check for evidence of a GI bleed (melena or bright red blood).

• Head CT: Essential if there are any new focal neurologic deficits, signs of trauma, or if the diagnosis is unclear.

• Lumbar Puncture: If you have any suspicion for meningitis or encephalitis.

Management Strategy: Your Step-by-Step Approach

Treatment is two-fold: treat the underlying trigger and lower ammonia levels.

First-Line Therapy: Lactulose Dosage Guidelines

Lactulose is the cornerstone of HE treatment. It works through two main mechanisms:

1. Gut Acidification: It's metabolized by gut bacteria into lactic acid, which lowers the pH of the colon. This converts absorbable ammonia (NH₃) into non-absorbable ammonium (NH₄⁺), trapping it in the gut to be excreted.

2. Catharsis: It's an osmotic laxative that speeds up GI transit, reducing the time for ammonia production and absorption.

Dosing:

• Initial Dose: Give 30-45 mL orally or via NG tube.

• Titration: Repeat the dose every 1-2 hours until the patient has a bowel movement.

• Maintenance: The goal is to titrate the dose to achieve 2-4 soft bowel movements per day.

• For unconscious patients (Grade 3-4 HE): If the patient cannot swallow safely, use an NG tube. A lactulose enema (300 mL of lactulose in 700 mL of water, retained for 30-60 minutes) is also an effective option.

Adding Backup: Rifaximin for Hepatic Encephalopathy

Rifaximin is a non-absorbable antibiotic. It works by reducing the population of ammonia-producing bacteria in the gut.

According to guidelines from the American College of Gastroenterology (ACG) and the American Association for the Study of Liver Diseases (AASLD), rifaximin is a key player.

• In acute HE: Consider adding rifaximin (550 mg twice daily) to lactulose, especially in severe cases or if the patient isn't improving with lactulose alone. Studies show the combination can lead to faster resolution of HE, shorter hospital stays, and lower mortality.

• For secondary prevention: Rifaximin is also used to prevent recurrent episodes of HE in patients who have recovered.

Advanced Therapies: What About Liver Dialysis (MARS)?

You might hear about a therapy called Molecular Adsorbent Recirculating System (MARS). This is essentially a form of "liver dialysis" that selectively removes albumin-bound toxins (like ammonia and bilirubin) that traditional hemodialysis can't.

• Potential Role: MARS can temporarily improve the degree of encephalopathy and can be used as a "bridge" to keep a patient stable while they await a liver transplant.

• The Evidence: The data is mixed. Major randomized trials have not shown a clear survival benefit for patients with acute-on-chronic liver failure. Therefore, its role remains unclear, and it's not widely available.

Key Takeaways for Your Next Shift

When you encounter a confused patient with liver disease, think HE.

1. HE is a diagnosis of exclusion. Your first job is to rule out other dangerous causes of altered mental status.

2. Find the trigger! Actively search for and treat infections, GI bleeding, electrolyte problems, and dehydration.

3. Start lactulose early. The initial goal is a bowel movement; the long-term goal is 2-4 soft stools per day.

4. Consider adding rifaximin, especially for severe HE or for patients who don't respond quickly to lactulose.

5. Ammonia levels can be tricky. A normal level in a comatose patient is useful for ruling out HE, but an elevated level is non-specific. Treat the patient, not the number.

6. For patients with severe stage 3 hepatic encephalopathy or Grade 4, prioritize airway protection (they are at high risk of aspiration) and manage them in an ICU setting.

References:

• Vilstrup H, Amodio P, Bajaj J, et al. Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver. Hepatology. 2014;60(2):715-735.

• Bajaj JS, Cordoba J, Mullen KD, et al. ACG Clinical Guideline: Hepatic Encephalopathy. Am J Gastroenterol. 2014;109(8):1159-1179.